CSIMarket


Puma Biotechnology Inc   (PBYI)
Other Ticker:  
 

Puma Biotechnology Inc

PBYI's Fundamental analysis








Puma Biotechnology Inc 's sales fell by -1.73 % in III. Quarter 2023 from the same quarter a year ago. Ranking at No. 719

Major Pharmaceutical Preparations industry recorded deterioration of revenues by -4.74 %

Puma Biotechnology Inc realized net income compared to net loss a year ago in III. Quarter 2023

More on PBYI's Growth


Puma Biotechnology Inc
current PE on trailing twelve month basis is below Major Pharmaceutical Preparations industry average.

Company is currently trading with Price to Cash flow multiple of 66.75 in trailing twelve-month period.
Company
59.03
PE TTM   
Industry
283.72
PE TTM    
Company's Price to Sales ratio is at 1.12.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.79.


More on PBYI's Valuation
 
 Total Debt (Millions $) 99
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 498,117
 Net Income/Employee (TTM) $ 8,080
 Receivable Turnover (TTM) 6.96
 Tangible Book Value (Per Share $) -0.51

Puma Biotechnology Inc
current PE on trailing twelve month basis is below Major Pharmaceutical Preparations industry average.

Company is currently trading with Price to Cash flow multiple of 66.75 in trailing twelve-month period.
Company
59.03
PE TTM   
Industry
283.72
PE TTM    
Company's Price to Sales ratio is at 1.12.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.79.

Puma Biotechnology Inc Price to Book Ratio is at 6.62 lower than Indusry Avg. of 1293.67. and higher than S&P 500 Avg. of -2037.67

More on PBYI's Valuation

  Market Capitalization (Millions $) 256
  Shares Outstanding (Millions) 48
  Employees 460
  Revenues (TTM) (Millions $) 229
  Net Income (TTM) (Millions $) 4
  Cash Flow (TTM) (Millions $) 4
  Capital Exp. (TTM) (Millions $) -13
  Total Debt (Millions $) 99
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ 498,117
  Net Income/Employee(TTM) $ 8,080
  Receivable Turnover Ratio (TTM) 6.96
  Tangible Book Value (Per Share $) -0.51

  Market Capitalization (Millions $) 256
  Shares Outstanding (Millions) 48
  Employees 460
  Revenues (TTM) (Millions $) 229
  Net Income (TTM) (Millions $) 4
  Cash Flow (TTM) (Millions $) 4
  Capital Exp. (TTM) (Millions $) -13


    PBYI's Profitability Comparisons
Puma Biotechnology Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2023 to 15.3 % from 8.96 % in II. Quarter.

Puma Biotechnology Inc net profit margin of 10.33 % is currently ranking no. 48 in Major Pharmaceutical Preparations industry, ranking no. 102 in Healthcare sector and number 1321 in S&P 500.





  Ratio
   Capital Ratio (MRQ) 1.86
  Total Debt to Equity (MRQ) 2.56
  Tangible Leverage Ratio (MRQ) -
  Asset Turnover Ratio (TTM) 1.11
  Inventory Turnover Ratio (TTM) 10.16



Puma Biotechnology Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2023 to 15.3 % from 8.96 % in II. Quarter.

Puma Biotechnology Inc net profit margin of 10.33 % is currently ranking no. 48 in Major Pharmaceutical Preparations industry, ranking no. 102 in Healthcare sector and number 1321 in S&P 500.

More on PBYI's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com